Journal of Clinical Oncology
Articles in this Issue
Liquid biopsy for detection of DDR gene alterations in metastatic prostate cancer (mPC): Diagnostic performance and clinical correlations.
218 Background: DNA-damage-repair (DDR) gene alterations, particularly those involving BRCA1/2 genes, are clinically relev...
Patient and trial design factors influencing participation in prospective bladder and kidney cancer clinical trials.
655 Background: Patients on clinical trials with renal cell carcinoma (RCC) or urothelial carcinoma (UC) have better outco...
PSMA PET versus conventional imaging in metastatic prostate cancer: Evaluation of disease volume classification in a veteran cohort.
21 Background: Conventional imaging (CI), including CT and bone scans, has traditionally guided treatment decisions for pa...
Real-world data on patients’ characteristics guiding physicians’ choice of first-line treatment for advanced urothelial carcinoma: Is there still a place for platinum-based chemotherapy?
690 Background: The treatment landscape for patients with advanced urothelial carcinoma (mUC) has evolved rapidly in recen...
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated mCRPC from a phase 1/2 study: Analyses according to prior treatment with lutetium 177 (177Lu)-PSMA-617.
176 Background: 177Lu-PSMA-617 (Lu 177) has reported improved outcomes in metastatic hormone sensitive and castration resi...
End-of-life treatment patterns in patients (pts) with metastatic renal cell carcinoma (mRCC).
466 Background: The treatment landscape of mRCC has rapidly evolved in recent years, particularly with the introduction of...
Polypharmacy and potential drug–drug interactions with novel androgen receptor signaling inhibitors (ARSIs) in patients (pts) with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) in a real-world setting.
346 Background: Patients (pts) with nmCRPC are typically elderly, with comorbidities often leading to polypharmacy and a h...
Association of enriched <i>YES1</i> tumor expression at the stromal interface with overall survival in clear cell renal cell carcinoma when treated with first-line immune checkpoint blockade.
522 Background: Immune checkpoint blockade (ICB) has improved response rates for patients with advanced clear cell renal c...
Treatment outcomes of patients (pts) with small cell or neuroendocrine carcinoma (SC/NE) of the prostate: A single-institution experience.
111 Background: Neuroendocrine carcinoma of the prostate, including the small cell subset, is aggressive with poor prognos...
Metabolic reprogramming in chromophobe renal cell carcinoma: Transcriptomic insights into the transition from indolent to aggressive disease.
530 Background: Chromophobe renal cell carcinoma (CHRCC) is an uncommon subtype that is usually indolent but becomes aggre...
Predicting clear cell subtype for kidney tumors from cross-sectional imaging using artificial intelligence.
429 Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer in adults. The standar...
Efficacy of <sup>177</sup> Lu-PSMA-617 in neuroendocrine prostate cancer.
80 Background: The approval of Lutetium vipivotide tetraxetan ( 177 Lu-PSMA-617) f...
Inpatient outcomes of bladder cancer: Racial and socioeconomic disparities in a nationally representative sample (2020-2022).
873 Background: Bladder cancer is the sixth most common malignancy in the United States (U.S.) and continues to impose sub...
Molecular and clinical correlates of early-onset clear cell renal cell carcinoma (eoRCC): A real-world multi-omics analysis.
535 Background: From 2010-2019, eoRCC had 1,793 excess cases, the third largest increase after breast and colorectal cance...
Intermittent fasting in prostate cancer patients receiving androgen deprivation therapy.
TPS273 Background: Epidemiological studies suggest that diet can impact the incidence, progression, and response to treatm...
Liquid biopsy guided disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer (DECIDING-I study).
849 Background: Trimodal therapy remains the standard organ-sparing approach for muscle-invasive bladder cancer (MIBC), ye...
Kidney injury molecule‐1 (KIM-1) in localized and metastatic renal cell carcinoma (RCC): A meta-analysis and systematic review.
539 Background: Kidney Injury Molecule‐1 (KIM‐1) is a type 1 cell membrane glycoprotein, currently under investigation as...
Plasma cfChIP-seq to predict cell surface target expression in neuroendocrine prostate cancer.
254 Background: Treatment of prostate adenocarcinoma (PRAD) with androgen-receptor pathway inhibitors can drive resistance...
ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
TPS290 Background: Landmark randomized trials established the survival benefit of adding D to ADT in mCSPC. Building on th...
Educational representation of genitourinary malignancies in medical student curricula: A cross-sectional review of oncologic education in Caribbean and South American schools.
4 Background: Genitourinary (GU) malignancies, including prostate, bladder, renal, and testicular cancers, comprise a majo...
CCL21 as a treatment-linked prognostic biomarker in metastatic castration-resistant prostate cancer.
257 Background: Metastatic castration-resistant prostate cancer (mCRPC) is an immunologically “cold” tumor with a low-infl...
First-in-human assessment of actinium-225-prostate-specific membrane antigen ( <sup>225</sup> Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study.
19 Background: PSMA is a validated target in the treatment of mCRPC. We investigated 225...
Cross institutional comparison of the miR-371a-3p assay in pre-surgical germ cell tumor (GCT) patients.
621 Background: miR-371a-3p (miR371) is a promising biomarker in GCTs. Diagnostic parameters of miR371 in the literature u...
Pan-cancer assessment of deletions in COQ biosynthesis pathway genes associated with poor prognosis and potential benefit from BPM31510 intervention in kidney cancers.
500 Background: Defective energy metabolism has been established as a hallmark of cancer; however, the specific genetic ba...
Comprehensive genomic profiling in prostate cancer: Clinical relevance of BRCA1/2 pathogenic variants in the mCRPC.
210 Background: To delineate the genomic landscape of prostate cancer (PCa) and evaluate clinical outcomes of the PARP inh...